Loading...
Adherence to BCR-ABL Inhibitors: Issues for CML Therapy
Treatment for chronic myeloid leukemia (CML) has improved substantially in the last 20 years, especially since the introduction of oral BCR-ABL inhibitors a decade ago. However, for patients to reap the benefits of BCR-ABL inhibitors, they must likely be on therapy for the remainder of their lives....
Saved in:
| Published in: | Clin Lymphoma Myeloma Leuk |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2012
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4428159/ https://ncbi.nlm.nih.gov/pubmed/22633166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clml.2012.04.002 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|